Robert A. Mantei
28Patents
10h-index
73Co-inventors
78Inventor score
Filing activity: May 22, 1991 → Oct 7, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8563735B2 | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | Chemistry; Metallurgy | 70 | Active |
| US7772231B2 | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors | Human Necessities | 62 | Active |
| US8546399B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | Emerging Cross-Sectional Technologies | 57 | Active |
| US8586754B2 | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | Chemistry; Metallurgy | 55 | Active |
| US8557983B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Chemistry; Metallurgy | 40 | Active |
| US8580794B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Chemistry; Metallurgy | 35 | Active |
| US7491718B2 | Sulfonamides having antiangiogenic and anticancer activity | Chemistry; Metallurgy | 25 | Expired |
| US9034875B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Chemistry; Metallurgy | 16 | Active |
| US9029404B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Chemistry; Metallurgy | 16 | Active |
| US9174982B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Emerging Cross-Sectional Technologies | 15 | Active |
| US9072748B2 | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | Chemistry; Metallurgy | 9 | Active |
| US9303025B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Emerging Cross-Sectional Technologies | 9 | Active |
| US9045420B2 | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | Chemistry; Metallurgy | 9 | Active |
| US9073855B2 | BCL-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseases | Chemistry; Metallurgy | 9 | Active |
| US9125913B2 | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | Chemistry; Metallurgy | 8 | Active |
| US5268374A | Non-peptide renin inhibitors | Chemistry; Metallurgy | 8 | Expired |
| US7211595B2 | Farnesyltransferase inhibitors | Chemistry; Metallurgy | 4 | Expired |
| US10035800B2 | Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors | Chemistry; Metallurgy | 3 | Active |
| US9296741B2 | Bromodomain inhibitors | Chemistry; Metallurgy | 3 | Active |
| US9321764B2 | Dihydro-pyrrolopyridinone inhibitors | Chemistry; Metallurgy | 2 | Active |
| US7056925B2 | Urea kinase inhibitors | Chemistry; Metallurgy | 1 | Expired |
| US7323570B2 | Farnesyltransferase inhibitors | Chemistry; Metallurgy | 1 | Active |
| US8354422B2 | Pyrimidine inhibitors of kinase activity | Chemistry; Metallurgy | 1 | Active |
| US8486933B2 | Pyrimidine inhibitors of kinase activity | Chemistry; Metallurgy | 1 | Active |
| US9051315B2 | Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.